Evidence map›Paper›PMID 39262781›Full record

ArticleiScience2024

Exploring the role of KIR3DL2 on NK cells in hepatocellular carcinoma and its potential prognostic implications.

Jie Zhu, Anli Jin, Baishen Pan, Wei Guo, Wenjing Yang, Beili Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie ZhuDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Anli JinDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Baishen PanDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wei GuoDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wenjing YangDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Beili WangDepartment of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a globally prevalent malignancy with a high recurrence rate, significantly impacting prognosis and survival. This study aims to identify prognostic molecular markers using single-cell sequencing of tumors and adjacent tissues in primary and recurrent HCC patients. We analyzed single-cell sequencing data from tumor and adjacent normal tissues of primary and recurrent HCC cases to compare immune cell quantity and gene expression profiles. Recurrent HCC patients exhibited a significant reduction in infiltrating NK cells expressing KIR3DL2. Pseudotemporal and cell communication analyses revealed these KIR3DL2

Indexed as

BioinformaticsCancerImmune response

Identifiers

PMID39262781
PMCPMC11388180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.